{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T19:27:33Z","timestamp":1793474853682,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["MAECI-2023\\u201323683592 - ITALIA-SOUTH AFRICA 2023\\u20132025-NARA"],"award-info":[{"award-number":["MAECI-2023\\u201323683592 - ITALIA-SOUTH AFRICA 2023\\u20132025-NARA"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"NRF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.biopha.2025.118403","type":"journal-article","created":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T18:44:02Z","timestamp":1754160242000},"page":"118403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Drug-like molecules targeting androgen receptor's allosteric binding sites selected by augmented AI and high-throughput screening as antitumor agents against prostate cancer"],"prefix":"10.1016","volume":"190","author":[{"given":"Francesca","family":"Bruzzese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Iannelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Serena","family":"Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Addi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Grumetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Budillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4213-5416","authenticated-orcid":false,"given":"Njabulo Joyfull","family":"Gumede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118403_bib1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41391-020-00310-3","article-title":"Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors","volume":"24","author":"Saad","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.biopha.2025.118403_bib2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/ijun.12263","article-title":"New treatments for patients with nonmetastatic castration-resistant prostate cancer: a nursing perspective","volume":"15","author":"Olivier","year":"2021","journal-title":"Int. J. Urol. Nurs."},{"key":"10.1016\/j.biopha.2025.118403_bib3","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1016\/j.bmc.2008.02.031","article-title":"Potent anti-prostate cancer agents derived from a novel androgen receptor down-regulating agent","volume":"16","author":"Purushottamachar","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118403_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/aps.2014.18","article-title":"Androgen receptor: structure, role in prostate cancer and drug discovery","volume":"36","author":"Tan","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.biopha.2025.118403_bib5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.canep.2009.10.003","article-title":"Breast cancer as a global health concern","volume":"33","author":"Coughlin","year":"2009","journal-title":"Cancer Epidemiol."},{"key":"10.1016\/j.biopha.2025.118403_bib6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejca.2016.04.002","article-title":"Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: a literature based meta-analysis of randomized trials","volume":"61","author":"Roviello","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118403_bib7","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S1470-2045(13)70442-X","article-title":"Economic burden of cancer across the european union: a population-based cost analysis","volume":"14","author":"Luengo-Fernandez","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2025.118403_bib8","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1016\/j.ejca.2015.07.027","article-title":"Survival of Male genital cancers (prostate, testis, and penis) in Europe 1999-2007: results from the EUROCARE-5 study","volume":"51","author":"Trama","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118403_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, Castration-Sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118403_bib10","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic Hormone-Sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118403_bib11","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2025.118403_bib12","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118403_bib13","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118403_bib14","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2025.118403_bib15","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, Castration-Resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118403_bib16","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and Metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118403_bib17","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, Castration-Resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118403_bib18","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118403_bib19","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118403_bib20","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.118403_bib21","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter Radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118403_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.165","article-title":"Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells","volume":"4","author":"Milone","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2025.118403_bib23","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0960-0760(03)00070-0","article-title":"Effects of novel 17\u03b1-hydroxylase\/C17, 20-lyase (P450 17, C.Y.P. 17) inhibitors on androgen biosynthesis in vitro and in vivo","volume":"84","author":"Haidar","year":"2003","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.biopha.2025.118403_bib24","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/annonc\/mdt571","article-title":"Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial","volume":"25","author":"Sternberg","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2025.118403_bib25","first-page":"692","article-title":"Ligand-Independent and Tissue-Selective androgen receptor inhibition by pyrvinium","volume":"9","author":"Lim","year":"2014","journal-title":"A. C. S. Chem. Biol."},{"key":"10.1016\/j.biopha.2025.118403_bib26","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1021\/cr020456u","article-title":"Chemistry and structural biology of androgen receptor","volume":"105","author":"Gao","year":"2005","journal-title":"Chem. Rev."},{"key":"10.1016\/j.biopha.2025.118403_bib27","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1021\/bi102059z","article-title":"Mechanism of androgen receptor antagonism by bicalutamide in the treatment of prostate cancer","volume":"50","author":"Osguthorpe","year":"2011","journal-title":"Biochemistry"},{"key":"10.1016\/j.biopha.2025.118403_bib28","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1021\/ci800149w","article-title":"Computationally identified novel Diphenyl- and phenylpyridine androgen receptor antagonist structures","volume":"48","author":"S\u00f6derholm","year":"2008","journal-title":"J. Chem. Inf. Model"},{"key":"10.1016\/j.biopha.2025.118403_bib29","doi-asserted-by":"crossref","first-page":"7693","DOI":"10.1021\/jm201059s","article-title":"Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists","volume":"54","author":"Guo","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118403_bib30","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1210\/me.2011-1281","article-title":"Allosteric conversation in the androgen receptor Ligand-Binding domain surfaces","volume":"26","author":"Grosdidier","year":"2012","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.biopha.2025.118403_bib31","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1016\/j.bmc.2017.04.018","article-title":"Synthesis, and biological evaluation of novel selective androgen receptor modulators (SARMs) part III: discovery of 4-(5-oxopyrrolidine-1-yl) benzonitrile derivative 2f as a clinical candidate","volume":"25","author":"Aikawa","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118403_bib32","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1371\/journal.pbio.0020274","article-title":"Recognition and accommodation at the androgen receptor coactivator binding interface","volume":"2","author":"Hur","year":"2004","journal-title":"Plos Biol."},{"key":"10.1016\/j.biopha.2025.118403_bib33","doi-asserted-by":"crossref","first-page":"8224","DOI":"10.1021\/jm500101h","article-title":"Targeting the androgen receptor with steroid conjugates","volume":"57","author":"Levine","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118403_bib34","unstructured":"I. Wallach, M. Dzamba, A. Heifets, AtomNet: a deep convolutional neural network for bioactivity prediction in structure-based drug discovery, DOIs: 10.48550\/arXiv.1510.02855. (Accessed: 6 June 2022)."},{"key":"10.1016\/j.biopha.2025.118403_bib35","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.cmet.2019.08.023","article-title":"Parkinson's disease subset and Miro1 reducer rescues neuron loss in Parkinson's models","volume":"30","author":"Hsieh","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.biopha.2025.118403_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202004846","article-title":"spop and otud7a control e.w.s.\u2013fli1 protein stability to govern ewing sarcoma growth","volume":"8","author":"Su","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.biopha.2025.118403_bib37","first-page":"21579","article-title":"Author correction: AI is a viable alternative to high throughput screening: a 318-target study","volume":"14","author":"The Atomwise AIMS Program","year":"2024","journal-title":"Nat. Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118403_bib38","doi-asserted-by":"crossref","first-page":"9763","DOI":"10.1021\/jm301008n","article-title":"Rules for identifying potentially reactive or promiscuous compounds","volume":"55","author":"Bruns","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118403_bib39","series-title":"Epik, Schr\u00f6dinger","author":"Schr\u00f6dinger Release 2021-2","year":"2021"},{"key":"10.1016\/j.biopha.2025.118403_bib40","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s10822-007-9133-z","article-title":"Epik: a software program for pka prediction and protonation state generation for drug-like molecules","volume":"21","author":"Shelley","year":"2007","journal-title":"J. Comp. Aided Mol. Des."},{"key":"10.1016\/j.biopha.2025.118403_bib41","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1021\/acs.jctc.8b01026","article-title":"OPLS3e: extending force field coverage for Drug-Like small molecules","volume":"15","author":"Roos","year":"2019","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.biopha.2025.118403_bib42","unstructured":"RCSB Protein Data Bank \u3008http:\/\/www.rcsb.org\/\u3009 (Accessed: 24 November 2022)."},{"key":"10.1016\/j.biopha.2025.118403_bib43","unstructured":"Schr\u00f6dinger Release 2021-2: Schr\u00f6dinger Suite 2021-2 Protein Preparation Wizard; Epik, Schr\u00f6dinger, LLC, New York, NY, 2021; Impact, Schr\u00f6dinger, LLC, New York, NY, 2018; Prime, Schr\u00f6dinger, LLC, New York, NY, 2021."},{"key":"10.1016\/j.biopha.2025.118403_bib44","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"\"Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments\"","volume":"27","author":"Sastry","year":"2013","journal-title":"J. Comput. Aid. Mol. Des."},{"key":"10.1016\/j.biopha.2025.118403_bib45","series-title":"Prime, Schr\u00f6dinger","author":"Schr\u00f6dinger Release 2021-2","year":"2021"},{"key":"10.1016\/j.biopha.2025.118403_bib46","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/prot.10613","article-title":"A hierarchical approach to All-Atom protein loop prediction","volume":"55","author":"Jacobson","year":"2004","journal-title":"Proteins Struct. Funct. Bioinforma."},{"key":"10.1016\/j.biopha.2025.118403_bib47","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0022-2836(02)00470-9","article-title":"On the role of crystal packing forces in determining protein sidechain conformations","volume":"320","author":"Jacobson","year":"2002","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.biopha.2025.118403_bib48","doi-asserted-by":"crossref","first-page":"11225","DOI":"10.1021\/ja9621760","article-title":"Development and testing of the OPLS All-Atom force field on conformational energetics and properties of organic liquids","volume":"118","author":"Jorgensen","year":"1996","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.biopha.2025.118403_bib49","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1021\/ja00214a001","article-title":"The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin","volume":"110","author":"Jorgensen","year":"1988","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.biopha.2025.118403_bib50","unstructured":"Schr\u00f6dinger Release 2021-2: Schr\u00f6dinger Suite 2021-2 Induced Fit Docking protocol; Glide, Schr\u00f6dinger, L.L.C., New York, NY, 2018; Prime, Schr\u00f6dinger, L.L.C., New York, NY, 2018."},{"key":"10.1016\/j.biopha.2025.118403_bib51","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/jcc.20267","article-title":"A fast, scalable method for the parallel evaluation of distance-limited pair wise particle interactions","volume":"26","author":"Shaw","year":"2005","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.biopha.2025.118403_bib52","doi-asserted-by":"crossref","DOI":"10.1063\/1.2431176","article-title":"A common, avoidable source of error in molecular dynamics integrators","volume":"126","author":"Lippert","year":"2007","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.biopha.2025.118403_bib53","doi-asserted-by":"crossref","first-page":"19559","DOI":"10.18632\/oncotarget.7195","article-title":"Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression","volume":"7","author":"Ciardiello","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2025.118403_bib54","first-page":"440","article-title":"Sequential fractionation and isolation of subcellular proteins from tissue or cultured cells","volume":"2","author":"Baghirova","year":"2015","journal-title":"Methods X"},{"key":"10.1016\/j.biopha.2025.118403_bib55","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1021\/acs.jcim.0c00116","article-title":"Rigorous free energy simulations in virtual screening","volume":"60","author":"Cournia","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.biopha.2025.118403_bib56","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1021\/acs.jcim.7b00564","article-title":"Relative binding free energy calculations in drug discovery: recent advances and practical considerations","volume":"57","author":"Cournia","year":"2017","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.biopha.2025.118403_bib57","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1021\/acs.jctc.1c00136","article-title":"Reliable and accurate solution to the induced fit docking problem for Protein\u2013Ligand binding","volume":"17","author":"Miller","year":"2021","journal-title":"J. Chem. Theory Comp."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225005979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225005979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T08:36:41Z","timestamp":1772786201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225005979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":57,"alternative-id":["S0753332225005979"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118403","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-like molecules targeting androgen receptor's allosteric binding sites selected by augmented AI and high-throughput screening as antitumor agents against prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118403","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118403"}}